Nektar Therapeutics Reports Positive Phase 2b Maintenance Data for Atopic Dermatitis Drug, Aligns with FDA for Phase 3

summarizeSummary

Nektar Therapeutics announced positive 36-week maintenance results for rezpegaldesleukin in moderate-to-severe atopic dermatitis, demonstrating durable efficacy and a favorable safety profile, and confirmed alignment with the FDA for planned Phase 3 trials starting in Q2 2026.

check_boxKey Events

• Positive Phase 2b Maintenance Results

  Rezpegaldesleukin demonstrated durable and deepening efficacy in moderate-to-severe atopic dermatitis over a 36-week maintenance period, with high rates of EASI-75, EASI-90, and vIGA-AD 0/1 responses.

• Increased EASI-100 Response Rates

  The 24 µg/kg monthly and quarterly dosing regimens showed a 2 to 5-fold increase in patients achieving complete skin clearance (EASI-100) by Week 52.

• Favorable Safety Profile

  The drug was well-tolerated with no new safety concerns identified during the maintenance period, and a low discontinuation rate due to adverse events (3.5%).

• FDA Alignment for Phase 3

  Nektar reached alignment with the FDA on the Phase 3 trial design, including a 24 µg/kg Q2W induction dose and co-primary endpoints of EASI-75 and an IGA-related endpoint.

auto_awesomeAnalysis

This 8-K filing is highly significant for Nektar Therapeutics as it provides strong positive clinical data for rezpegaldesleukin, its lead regulatory T-cell biologic for atopic dermatitis. The sustained efficacy and deepening of responses observed during the 36-week maintenance period, including a notable increase in EASI-100 response rates, suggest a compelling therapeutic profile. The consistent and favorable safety profile further de-risks the program. Crucially, the company has achieved alignment with the FDA on the Phase 3 trial design, which includes a clear path for induction and maintenance dosing regimens, and plans to initiate these pivotal trials in Q2 2026 with a target BLA filing in 2029. This progress significantly advances rezpegaldesleukin towards commercialization and validates its novel mechanism of action, positioning it as a potential best-in-class immune-modulator in a large market.